Skip to main content
CABR
NASDAQ Industrial Applications And Services

Caring Brands Secures Exclusive Global License for Emesyl Nausea Relief Product

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.1
Mkt Cap
$13.737M
52W Low
$0.056
52W High
$6
52W Position info
1862% above low
Off High info
82% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CABR has more than doubled off its 52-week low of $0.056 on light trading volume (0.4× avg).

Summary

Caring Brands has obtained an exclusive worldwide license to manufacture and market Itonis Pharmaceuticals' Emesyl nausea relief product, marking a significant expansion into the global OTC market.


Key Events · M&A and Partnerships · CABR

  • Exclusive Global License Secured

    Caring Brands, Inc. entered into an exclusive worldwide license agreement with Itonis Pharmaceuticals to manufacture, market, and sell the homeopathic Emesyl product for nausea relief.

  • Strategic Portfolio Expansion

    This agreement expands Caring Brands' health and wellness portfolio into the over-the-counter market, targeting a global nausea treatment market projected to exceed $6.23 billion by 2025.

  • Operational Responsibilities

    Caring Brands will assume full responsibility for Emesyl's manufacturing, marketing, sales strategy, and global distribution efforts.

  • Royalty and Equity Structure

    The company will pay an 8% royalty on net sales to Itonis and has the potential to earn 7% equity in Itonis for every $200,000 in Emesyl product sales.


Analysis · CABR · Industrial Applications And Services

This agreement represents a strategic expansion for Caring Brands, entering the over-the-counter nausea relief market with an exclusive worldwide license for the homeopathic Emesyl product. For a micro-cap company, securing rights to a product in a global market projected to exceed $6.23 billion by 2025 offers a significant growth opportunity and diversification of its health and wellness portfolio. While the company assumes manufacturing, marketing, and distribution responsibilities, and will pay an 8% royalty on net sales, the potential to earn equity in Itonis based on sales milestones provides an additional upside. Investors should monitor the company's progress in product launch and market penetration.

At the time of this filing, CABR was trading at $1.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.7M. The 52-week trading range was $0.06 to $6.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CABR - Latest Insights

CABR
Jul 17, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $1.31 info
Change: +$0.0134 (+1%) info
Market Cap: $13.183M info
CABR
Jul 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $1.31 info
Change: +$0.0134 (+1%) info
Market Cap: $13.183M info
CABR
Jul 16, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $1.31 info
Change: +$0.0334 (+3%) info
Market Cap: $13.183M info
CABR
Jul 14, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $1.31 info
Change: +$0.0034 (+0.26%) info
Market Cap: $13.183M info
CABR
Jun 01, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.31 info
Change: +$0.0881 (+7%) info
Market Cap: $13.183M info